February 12, 2021
The payoff
It goes without saying that the drug business is a very risky busines and the diabetes drug sector is no different. New drug development in particular can have a huge payoff but also carries with it an equal amount of risk. This is one reason we believed one of the best decisions ever made by Novo Nordisk was to repurpose Victoza, their once daily GLP-1, from a diabetes drug to a weight loss drug. Frankly the company had everything to gain and not much to lose, pardon the play on words.
Novo basically read the handwriting on the wall . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.
